Which genes are involved in the gene fusion related to Burkitt's lymphoma?

Burkitt's lymphoma is characterized by a specific genetic alteration involving the translocation of the MYC oncogene, located on chromosome 8, to one of the immunoglobulin loci, most commonly the immunoglobulin heavy chain locus (IGH) on chromosome 14. This translocation leads to the deregulation of MYC, resulting in its overexpression, which plays a critical role in cell proliferation and survival, ultimately contributing to the development of the lymphoma.

The Bcl2/IGH gene fusion, while significant in other types of lymphomas, such as follicular lymphoma, does not pertain to Burkitt's lymphoma. Similarly, gene fusions involving Rho or Fos with IGH are not associated with this disease's pathology. The specific fusion of C-myc with IGH is what drives the pathogenesis of Burkitt's lymphoma. Thus, the involvement of C-myc/IGH in this disease highlights the importance of MYC in oncogenic processes, specifically how its aberrations can lead to malignancies such as Burkitt's lymphoma.